According to a recent Reuters article, drug giant Eli Lilly and Co. has requested that the FDA de-authorize its COVID-19 antibody, bamlanivimab. The unique request isn’t linked to safety issues, but in response to new variants of the virus that could be resistant to bamlanivimab when used alone. The government agreed, and stopped distribution of the therapy last month. Facilities that still have supply are being shipped etesevimab to pair with it for a combination treatment that’s more effective.
Eli Lilly Asks FDA to Cancel COVID-19 Antibody Authorization
The pharmaceutical giant will use the antibody as part of a combination treatment for greater efficacy.
Apr 23, 2021
Sustainable Healthcare Packaging Solutions That Work
Industry leaders share proven strategies for reducing packaging emissions by up to 70% while meeting safety and regulatory requirements.
Read More
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
Downloads
